ONESOURCE · NSE
Onesource Specialty Pharma Limited
₹1,594.9
+0.94% (+₹14.9)
Prev. close
₹1,580
Volume
3,35,793
Delivery %
53.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Onesource Specialty Pharma Limited
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Neeraj Sharma
Headquarters
Bengaluru
Employees
1,674
Website
onesourcecdmo.comExchange
View on NSE ↗Key stats
Market cap
₹18,289.18 Cr
EPS (TTM)
₹-4.27
Beta (1Y · daily vs NIFTY 50)
-0.22
Shares float
6.58 Cr
EPS · quarter ended Jun 2026
₹2.18
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹38.71 Cr | ₹171.92 Cr | ₹1,444.85 Cr | ₹1,421.59 Cr | |
| EBITDA | ₹-261.44 Cr | ₹-184.92 Cr | ₹360.96 Cr | ₹298.57 Cr |
| ₹-799.83 Cr | ₹-391.17 Cr | ₹-17.97 Cr | ₹-73.80 Cr | |
| Diluted EPS | ₹-69.89 | ₹-34.18 | ₹-1.63 | ₹-6.44 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹2,008.81 Cr | ₹1,308.61 Cr | ₹7,550.24 Cr | ₹8,210.01 Cr | |
| ₹864.22 Cr | ₹571.17 Cr | ₹942.44 Cr | ₹1,503.94 Cr | |
| Stockholders' equity | ₹785.45 Cr | ₹395.71 Cr | ₹5,880.58 Cr | ₹5,831.29 Cr |
CWIP, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-162.77 Cr | ₹-107.21 Cr | ₹-67.85 Cr | ₹8.52 Cr | |
| Investing cash flow | ₹-67.83 Cr | ₹510.55 Cr | ₹-201.08 Cr | ₹-494.98 Cr |
| ₹118.32 Cr | ₹-390.54 Cr | ₹412.01 Cr | ₹359.44 Cr | |
| Capital expenditure | ₹-44.00 Cr | ₹-63.77 Cr | ₹-128.15 Cr | ₹-569.07 Cr |
| End cash position | ₹9.47 Cr | ₹22.26 Cr | ₹165.36 Cr | ₹38.34 Cr |
Dividends paid has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Dec 24(2Q) | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|
| Promoter | 37.77% | 34.25% | 29.79% | 29.77% | 29.93% | 30.48% |
| Public | 62.23% | 65.75% | 70.21% | 70.23% | 70.07% | 69.52% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Onesource Specialty Pharma Limited | ₹18,118.32 Cr | ₹1,594.9 | — | 3.11 | -1.3% | 0.26 | -1.6% | -14.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
11 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.